The Europe Cluster Headache Market should witness market growth of 3.4% CAGR during the forecast period (2022-2028).
Cluster headache signs often appear between the ages of 20 and 40. Researchers traditionally believed that males experienced these headaches more frequently. But now cluster headaches are known to have anequal impact on both men and women. Smokers and heavy drinkers are also more likely to get cluster headaches. Cluster headache sufferers frequently also have sleep apnea. The precise etiology of cluster headaches is still a mystery to specialists. The first branch of the trigeminal nerve and the hypothalamus, a brain component of the autonomic nervous system, is involved in cluster headaches and trigeminal autonomic cephalgia.
In activators of a fresh cycle (round) of headaches most people have cluster headaches infrequently, once per several months or years. The recurrence of headaches frequently seems related to seasonal fluctuations. Many mistakenly believe they have allergies or sinusitis due to the relationship. There may be a connection between cluster headaches and the hypothalamus, as is thought to be the case. The 'circadian clock,'a built-in timetable that changes in response to sunlight, is located in this brain area.
In Italy, 3.9 million individuals use nicotine more often or for the first time, including through electronic cigarettes. According to the report, one in five people who occasionally use heated tobacco products has switched to regular use, particularly among young people. 3.9 million individuals, or 9% of the population, started using tobacco or increased their use during the lockdown. Of them, 8.5% smoked more cigarettes per day on average, upping their daily intake from 10.9 to 12.7, and most of those who did so were female. These factors driving the region's market growth
The Germany market dominated the Europe Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $29.1 Million by 2028. The UK market is anticipated to grow at a CAGR of 2.5% during (2022-2028). Additionally, The France market would exhibit a CAGR of 4.1% during (2022-2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Cluster headache signs often appear between the ages of 20 and 40. Researchers traditionally believed that males experienced these headaches more frequently. But now cluster headaches are known to have anequal impact on both men and women. Smokers and heavy drinkers are also more likely to get cluster headaches. Cluster headache sufferers frequently also have sleep apnea. The precise etiology of cluster headaches is still a mystery to specialists. The first branch of the trigeminal nerve and the hypothalamus, a brain component of the autonomic nervous system, is involved in cluster headaches and trigeminal autonomic cephalgia.
In activators of a fresh cycle (round) of headaches most people have cluster headaches infrequently, once per several months or years. The recurrence of headaches frequently seems related to seasonal fluctuations. Many mistakenly believe they have allergies or sinusitis due to the relationship. There may be a connection between cluster headaches and the hypothalamus, as is thought to be the case. The 'circadian clock,'a built-in timetable that changes in response to sunlight, is located in this brain area.
In Italy, 3.9 million individuals use nicotine more often or for the first time, including through electronic cigarettes. According to the report, one in five people who occasionally use heated tobacco products has switched to regular use, particularly among young people. 3.9 million individuals, or 9% of the population, started using tobacco or increased their use during the lockdown. Of them, 8.5% smoked more cigarettes per day on average, upping their daily intake from 10.9 to 12.7, and most of those who did so were female. These factors driving the region's market growth
The Germany market dominated the Europe Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $29.1 Million by 2028. The UK market is anticipated to grow at a CAGR of 2.5% during (2022-2028). Additionally, The France market would exhibit a CAGR of 4.1% during (2022-2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Scope of the Study
By Distribution channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Others
By Type
- Episodic
- Chronic
By Drug Class
- Triptans
- Calcium Channel Blockers
- Ergot Derivatives
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Dr.Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Cluster Headache Market, by Distribution channel
1.4.2 Europe Cluster Headache Market, by Type
1.4.3 Europe Cluster Headache Market, by Drug Class
1.4.4 Europe Cluster Headache Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Cluster Headache Market by Distribution channel
3.1 Europe Drug Stores & Retail Pharmacies Market by Country
3.2 Europe Hospital Pharmacies Market by Country
3.3 Europe Others Market by Country
Chapter 4. Europe Cluster Headache Market by Type
4.1 Europe Episodic Market by Country
4.2 Europe Chronic Market by Country
Chapter 5. Europe Cluster Headache Market by Drug Class
5.1 Europe Triptans Market by Country
5.2 Europe Calcium Channel Blockers Market by Country
5.3 Europe Ergot Derivatives Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Cluster Headache Market by Country
6.1 Germany Cluster Headache Market
6.1.1 Germany Cluster Headache Market by Distribution channel
6.1.2 Germany Cluster Headache Market by Type
6.1.3 Germany Cluster Headache Market by Drug Class
6.2 UK Cluster Headache Market
6.2.1 UK Cluster Headache Market by Distribution channel
6.2.2 UK Cluster Headache Market by Type
6.2.3 UK Cluster Headache Market by Drug Class
6.3 France Cluster Headache Market
6.3.1 France Cluster Headache Market by Distribution channel
6.3.2 France Cluster Headache Market by Type
6.3.3 France Cluster Headache Market by Drug Class
6.4 Russia Cluster Headache Market
6.4.1 Russia Cluster Headache Market by Distribution channel
6.4.2 Russia Cluster Headache Market by Type
6.4.3 Russia Cluster Headache Market by Drug Class
6.5 Spain Cluster Headache Market
6.5.1 Spain Cluster Headache Market by Distribution channel
6.5.2 Spain Cluster Headache Market by Type
6.5.3 Spain Cluster Headache Market by Drug Class
6.6 Italy Cluster Headache Market
6.6.1 Italy Cluster Headache Market by Distribution channel
6.6.2 Italy Cluster Headache Market by Type
6.6.3 Italy Cluster Headache Market by Drug Class
6.7 Rest of Europe Cluster Headache Market
6.7.1 Rest of Europe Cluster Headache Market by Distribution channel
6.7.2 Rest of Europe Cluster Headache Market by Type
6.7.3 Rest of Europe Cluster Headache Market by Drug Class
Chapter 7. Company Profiles
7.1 Dr. Reddy’s Laboratories Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expenses
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Pfizer, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional & Segmental Analysis
7.6.4 Research & Development Expense
7.7 Fresenius SE & Co. KGaA
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Grünenthal GmbH
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.10. Arrotex Pharmaceuticals Pty Limited
7.10.1 Company Overview
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Methodology
LOADING...
